Home › Compare › NVNBW vs EQR

NVNBW vs EQR: Dividend Comparison 2026

NVNBW yields 28571.43% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NVNBW wins by $1.8174438113797412e+21M in total portfolio value
10 years
NVNBW
NVNBW
● Live price
28571.43%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.8174438113797412e+21M
Annual income
$1,805,016,220,998,010,500,000,000,000.00
Full NVNBW calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — NVNBW vs EQR

📍 NVNBW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNVNBWEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NVNBW + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
NVNBW pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NVNBW
Annual income on $10K today (after 15% tax)
$2,428,571.43/yr
After 10yr DRIP, annual income (after tax)
$1,534,263,787,848,309,000,000,000,000.00/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, NVNBW beats the other by $1,534,263,787,848,309,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NVNBW + EQR for your $10,000?

NVNBW: 50%EQR: 50%
100% EQR50/50100% NVNBW
Portfolio after 10yr
$908721905689870598144.00M
Annual income
$902,508,110,499,005,300,000,000,000.00/yr
Blended yield
99.32%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

NVNBW
No analyst data
Altman Z
-9.2
Piotroski
2/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NVNBW buys
0
EQR buys
0
No recent congressional trades found for NVNBW or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNVNBWEQR
Forward yield28571.43% ✓5.87%
Annual dividend / share$2.00$3.47 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$1.8174438113797412e+21M$47.8K ✓
Annual income after 10y$1,805,016,220,998,010,500,000,000,000.00 ✓$5,475.61
Total dividends collected$1.816625906206534e+21M$23.0K ✓
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: NVNBW vs EQR ($10,000, DRIP)

YearNVNBW PortfolioNVNBW Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$2,867,843$2,857,142.86$11,380$679.82+$2.86M → NVNBW
2$768,847,726$765,779,134.08$13,014$837.25+$768.83M → NVNBW
3$192,691,632,776$191,868,965,708.97$14,961$1,036.20+$192691.62M → NVNBW
4$45,147,257,398,343$44,941,077,351,272.53$17,297$1,289.22+$45147257.38M → NVNBW
5$9,889,057,995,779,864$9,840,750,430,363,638.00$20,121$1,613.15+$9889057995.76M → NVNBW
6$2,025,084,628,942,200,600$2,014,503,336,886,716,000.00$23,561$2,030.84+$2025084628942.18M → NVNBW
7$387,709,524,857,534,600,000$385,542,684,304,566,450,000.00$27,783$2,573.54+$387709524857534.63M → NVNBW
8$69,399,422,486,233,860,000,000$68,984,573,294,636,305,000,000.00$33,013$3,284.39+$69399422486233856.00M → NVNBW
9$11,614,570,450,215,628,000,000,000$11,540,313,068,155,356,000,000,000.00$39,547$4,223.51+$11614570450215628800.00M → NVNBW
10$1,817,443,811,379,741,200,000,000,000$1,805,016,220,998,010,500,000,000,000.00$47,791$5,475.61+$1.8174438113797412e+21M → NVNBW

NVNBW vs EQR: Complete Analysis 2026

NVNBW — Stock

enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of venous Chronic Venous Insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg; and enVVe, a non-surgical, transcatheter based replacement venous valve for the treatment of CVI. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

Full NVNBW Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this NVNBW vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NVNBW vs SCHDNVNBW vs JEPINVNBW vs ONVNBW vs KONVNBW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.